Compare ADMA Biologics Inc (ADMA) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Capri Holdings Ltd — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Capri Holdings Ltd trades at $17.79 (market cap $2.23B). The key difference: ADMA Biologics Inc and Capri Holdings Ltd are close in size by market cap. Which is the better fit depends on your goals.
| ADMA | CPRI | |
|---|---|---|
Market Cap | $2.13B | $2.23B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $27.66 |
52-Week Low | $7.60 | $16.79 |
Enterprise Value | $2.20B | $3.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CPRI trades at $19.41, up 2.37% today, amid mixed signals with bearish technical indicators but improving fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $0.22 versus $0.118, while revenue trends show stabilization after declines. The company's net income margin improved to 3.94% for 2026, though 2025 saw a significant loss. Analyst consensus is mixed with 44% buy ratings and a $23.43 price target, suggesting potential upside from current levels.
The outlook hinges on CPRI's turnaround execution, with risks including luxury demand volatility and high debt. Positive catalysts include projected FY2027 growth and cost management efforts. Investors should weigh the attractive P/S ratio of 0.65 against ongoing operational challenges and insider selling noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
